 Bi1015550 is a parade for inhibitor that has been shown to have antifibrotic properties in healthy male subjects and patients with idiopathic pulmonary fibrosis, IPF. In a phase 1 study, it was found to be safe and well tolerated when administered as a single dose or in multiple dosing regimens. Additionally, in a phase Ic study, it was found to be safe and well tolerated when administered at a dose of 18 mg twice daily for up to 12 weeks. This article was authored by Toby M. Mayer, Christina Schlecker, Doreen Lutke, and others.